Business Description
Shandong Xinhua Pharmaceutical Co Ltd
ISIN : US81943D1019
Share Class Description:
SHNXY: ADRTotal Employee Number:
7,240Compare
Compare
Traded in other countries / regions
000756.China00719.Hong KongXIN.GermanySHNXY.USA IPO Date
2017-03-08Description
Shandong Xinhua Pharmaceutical Co Ltd is a pharmaceutical products manufacturer based in China. It operates various segments namely Chemical raw materials, Preparations, Pharmaceutical intermediates and other products. The company is mainly engaged in the business of development, manufacture and sale of bulk pharmaceuticals, preparations and chemical products.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.9 | |||||
Equity-to-Asset | 0.59 | |||||
Debt-to-Equity | 0.27 | |||||
Debt-to-EBITDA | 3.79 | |||||
Interest Coverage | 10.74 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 3.18 | |||||
Beneish M-Score | -2.37 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 4.4 | |||||
3-Year EBITDA Growth Rate | -1.5 | |||||
3-Year EPS without NRI Growth Rate | -11.4 | |||||
3-Year FCF Growth Rate | -7.4 | |||||
3-Year Book Growth Rate | 7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 32.83 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 5.02 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.76 | |||||
Quick Ratio | 1.23 | |||||
Cash Ratio | 0.56 | |||||
Days Inventory | 63.52 | |||||
Days Sales Outstanding | 44.17 | |||||
Days Payable | 65.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Payout Ratio | 0.53 | |||||
3-Year Dividend Growth Rate | 18.6 | |||||
3-Year Average Share Buyback Ratio | -1 | |||||
Shareholder Yield % | 3.38 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 18.63 | |||||
Operating Margin % | 4.9 | |||||
Net Margin % | 2.99 | |||||
EBITDA Margin % | 4.28 | |||||
FCF Margin % | 3.52 | |||||
OCF Margin % | 4.59 | |||||
ROE % | 5.03 | |||||
ROA % | 2.85 | |||||
ROIC % | 5.56 | |||||
3-Year ROIIC % | 58.02 | |||||
ROC (Joel Greenblatt) % | 8.12 | |||||
ROCE % | 5.97 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 37.15 | |||||
Forward PE Ratio | 13.23 | |||||
PE Ratio without NRI | 30.83 | |||||
Shiller PE Ratio | 27.74 | |||||
Price-to-Owner-Earnings | 258.75 | |||||
PEG Ratio | 19.27 | |||||
PS Ratio | 1.12 | |||||
PB Ratio | 1.89 | |||||
Price-to-Tangible-Book | 2.11 | |||||
Price-to-Free-Cash-Flow | 30.19 | |||||
Price-to-Operating-Cash-Flow | 23.41 | |||||
EV-to-EBIT | 23.06 | |||||
EV-to-EBITDA | 23.06 | |||||
EV-to-Revenue | 0.99 | |||||
EV-to-FCF | 27.46 | |||||
Price-to-GF-Value | 0.83 | |||||
Price-to-Projected-FCF | 1.73 | |||||
Price-to-DCF (Earnings Based) | 1.05 | |||||
Price-to-DCF (FCF Based) | 2.37 | |||||
Price-to-Median-PS-Value | 0.86 | |||||
Price-to-Graham-Number | 1.7 | |||||
| Price-to-Net-Current-Asset-Value | 30.32 | |||||
Earnings Yield (Greenblatt) % | 4.34 | |||||
FCF Yield % | 3.81 | |||||
Forward Rate of Return (Yacktman) % | -1.06 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:SHNXY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shandong Xinhua Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,240.191 | ||
| EPS (TTM) ($) | 0.552 | ||
| Beta | 0.0061 | ||
| 3-Year Sharpe Ratio | -61.75 | ||
| 3-Year Sortino Ratio | -3.46 | ||
| Volatility % | 1.91 | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | - | ||
| 20-Day SMA ($) | 18.19 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 18.19 - 18.19 | ||
| Shares Outstanding (Mil) | 69.67 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shandong Xinhua Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shandong Xinhua Pharmaceutical Co Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| USD 0.219885 Cash Dividend | 2026-07-13 | In 5 days | ||
| USD 0.347595 Cash Dividend | 2025-07-08 | 18.19 (+0.00%) | ||
| USD 0.035077 Cash Dividend | 2024-09-05 | 18.19 (+0.00%) | ||
| USD 0.350441 Cash Dividend | 2024-07-22 | 18.19 (+0.00%) |
Show
Entries
Shandong Xinhua Pharmaceutical Co Ltd Frequently Asked Questions
What is Shandong Xinhua Pharmaceutical Co Ltd(SHNXY)'s stock price today?
The current price of SHNXY is $18.19. The 52 week high of SHNXY is $18.19 and 52 week low is $18.19.
When is next earnings date of Shandong Xinhua Pharmaceutical Co Ltd(SHNXY)?
The next earnings date of Shandong Xinhua Pharmaceutical Co Ltd(SHNXY) is .
Does Shandong Xinhua Pharmaceutical Co Ltd(SHNXY) pay dividends? If so, how much?
Shandong Xinhua Pharmaceutical Co Ltd(SHNXY) does not pay dividend.
Guru Commentaries on OTCPK:SHNXY
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Shandong Xinhua Pharmaceutical Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers